Jasper Therapeutics (JSPR)

Executive Summary

Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, a first-in-class monoclonal antibody designed to enable safer, chemotherapy-free conditioning for hematopoietic stem cell transplants and gene therapies. By selectively depleting host stem cells, briquilimab aims to reduce severe toxicities associated with traditional conditioning regimens, potentially expanding curative transplant access to elderly and medically vulnerable patients. The company is publicly traded (NASDAQ: JSPR) and has completed several early-phase trials, though its lead pipeline has shifted focus toward inflammatory indications. Currently, Jasper is conducting two active trials evaluating briquilimab in chronic urticaria: a Phase 2 study in chronic urticaria (NCT06736262) with completion expected in September 2026, and a Phase 1/2 trial in chronic spontaneous urticaria (NCT06162728) completing in October 2026. Data readouts from these studies could provide proof-of-concept in a large, underserved market and support potential registration pathways. While earlier trials in hematologic malignancies and asthma were discontinued, briquilimab's safety profile and novel mechanism position Jasper for value creation if urticaria data are positive. The company remains a high-risk, high-reward opportunity given its early clinical stage and dependence on upcoming results.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Topline Data for Briquilimab in Chronic Urticaria50% success
• Q4 2026Phase 1/2 Data for Briquilimab in Chronic Spontaneous Urticaria45% success
• TBDPotential Partnership or Financing for Briquilimab30% success